The hidden epidemic of hepatitis C virus infection in the United States: Occult transmission and burden of disease

Topics in Antiviral Medicine

Volumn 21, Issue 1, 2013, Pages 15-19

  Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; TELAPREVIR;

ARTICLE; EPIDEMIC; FOLLOW UP; HEALTH CARE; HEALTH DISPARITY; HEALTH IMPACT ASSESSMENT; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SCREENING TEST; UNITED STATES; VIRUS TRANSMISSION;

AGE FACTORS; EPIDEMICS; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; UNITED STATES;

EID: 84878842612     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72.
2. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537-541.
3. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-1144.
4. Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? Hepatology. 2013;57(3):917-924.
5. Scheinmann R, Hagan H, Lelutiu-Weinberger C, et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 2007;89(1):1-12.
6. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171(3):242-248.
7. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):588-564.
8. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care. 2011;17(8):548-555.
9. Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18(7):474-481.
10. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-1055.
11. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6):1652-1661.
12. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263-270.
13. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436-442.
14. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17-e24.